Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M; EVEREST trial investigators. Lanfear DE, et al. Among authors: gheorghiade m. Circ Heart Fail. 2013 Jan;6(1):47-52. doi: 10.1161/CIRCHEARTFAILURE.112.970012. Epub 2012 Dec 12. Circ Heart Fail. 2013. PMID: 23239836 Free PMC article. Clinical Trial.
Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.
Pang PS, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni AP, Grinfeld L, Zannad F, Burnett JC Jr, Ouyang J, Udelson JE, Konstam MA. Pang PS, et al. Among authors: gheorghiade m. Am Heart J. 2011 Jun;161(6):1067-72. doi: 10.1016/j.ahj.2011.02.027. Am Heart J. 2011. PMID: 21641352 Clinical Trial.
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M; EVEREST Investigators. Blair JE, et al. Among authors: gheorghiade m. Eur Heart J. 2011 Oct;32(20):2563-72. doi: 10.1093/eurheartj/ehr238. Epub 2011 Jul 23. Eur Heart J. 2011. PMID: 21785107 Clinical Trial.
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.
Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F. Gheorghiade M, et al. Heart Fail Rev. 2012 May;17(3):485-509. doi: 10.1007/s10741-011-9280-0. Heart Fail Rev. 2012. PMID: 21932146
Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial.
Ambrosy AP, Vaduganathan M, Huffman MD, Khan S, Kwasny MJ, Fought AJ, Maggioni AP, Swedberg K, Konstam MA, Zannad F, Gheorghiade M; EVEREST trial investigators. Ambrosy AP, et al. Among authors: gheorghiade m. Eur J Heart Fail. 2012 Mar;14(3):302-11. doi: 10.1093/eurjhf/hfs007. Eur J Heart Fail. 2012. PMID: 22357577 Free article.
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
Mentz RJ, Schmidt PH, Kwasny MJ, Ambrosy AP, O'Connor CM, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Gheorghiade M. Mentz RJ, et al. Among authors: gheorghiade m. J Card Fail. 2012 Jul;18(7):515-23. doi: 10.1016/j.cardfail.2012.04.010. Epub 2012 Jun 4. J Card Fail. 2012. PMID: 22748484 Clinical Trial.
Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
Greene SJ, Harinstein ME, Vaduganathan M, Subačius H, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Butler J, Gheorghiade M; EVEREST Trial Investigators. Greene SJ, et al. Among authors: gheorghiade m. Am J Cardiol. 2012 Dec 1;110(11):1657-62. doi: 10.1016/j.amjcard.2012.07.035. Epub 2012 Aug 21. Am J Cardiol. 2012. PMID: 22917555 Clinical Trial.
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, O'Connor CM, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiade M. Mentz RJ, et al. Among authors: gheorghiade m. Eur J Heart Fail. 2013 Jan;15(1):61-8. doi: 10.1093/eurjhf/hfs139. Epub 2012 Sep 11. Eur J Heart Fail. 2013. PMID: 22968743 Free PMC article. Clinical Trial.
Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA. Shah AN, et al. Among authors: gheorghiade m. Am J Cardiol. 2012 Dec 15;110(12):1803-8. doi: 10.1016/j.amjcard.2012.08.016. Epub 2012 Sep 19. Am J Cardiol. 2012. PMID: 22999071
719 results